Kathy Robinson, PhD

Kathy Robinson, PhD

Associate Professor
Center for Clinical Research

    About me

    Kathy Robinson has been involved with medical research for more than 20 years. Throughout that time, she has collaborated with many excellent clinicians and discovery science researchers to secure grants and move new cardiovascular and cancer treatments forward. 

    She enjoys meeting patients and is grateful for all of those who enroll in a clinical trial. Through these trials the research department learns so much from those who are willing to enroll. These clinical trials can lead to newly developed treatments. Robinson finds each patient is unique and brings a fresh perspective to studies. She looks forward to a continued collaboration with the faculty of SIU School of Medicine.

    Gender

    Female

    Education & training

    Doctorate Degree
    Southern Illinois University, Carbondale, IL
    Undergraduate Degree
    BS, Eastern Illinois University, Charleston, IL
    Fellowship
    Research Fellowship, Prairie Education and Research Cooperative, Springfield, IL

    Clinical trials

    Trial
    Simmons Cancer Institute

    ASND0029 "IL Believe": A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in

    Active recruiting

    This study is investigating experimental drugs TransCon IL-2 β/γ and TransCon TLR7/8 for the treatment of a

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    KO-MEN-008: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

    Active recruiting

    Examining the safety, tolerability, and effectiveness of investigational drug ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia. The study drug will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    BC-IMT-04: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

    Active recruiting

    This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

    Active recruiting

    This trial looks at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors (NSCLC, HNSCC).

    Contact: Kathy Robinson 217-545-1946
    Trial
    Urology

    A Randomized Open-Label Phase 2/3 Study of BT8009 Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

    Active recruiting

    The main objective of the study is to measure how safe and effective BT8009 (zelenectide pevedotin) is when used alone and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC).

    Contact: Kathy Robinson 217-545-1946
    Trial
    Urology

    A Randomized Open-Label Phase 2/3 Study of BT8009 Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

    Active recruiting

    The main objective of the study is to measure how safe and effective BT8009 (zelenectide pevedotin) is when used alone and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC).

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

    Active recruiting

    The purpose of the study is to test BGB-11417 (alone, with dexamethasone, and with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma who test positive for t(11;14). .

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk

    Active recruiting

    The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).

    Contact: Kathy Robinson 217-545-1946